Equities

Cue Biopharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Cue Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.6952
  • Today's Change0.003 / 0.46%
  • Shares traded66.63k
  • 1 Year change-29.06%
  • Beta1.5191
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

  • Revenue in USD (TTM)7.99m
  • Net income in USD-40.58m
  • Incorporated2014
  • Employees41.00
  • Location
    Cue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
  • Phone+1 (617) 949-2680
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cuebiopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Precision BioSciences Inc51.14m-21.99m48.12m107.00--0.9279--0.941-2.01-2.016.474.680.3309--58.35473,527.80-14.22-26.22-16.69-33.68-----42.99-87.80----0.3117--40.9825.30116.85---59.31--
vTv Therapeutics Inc17.00k-18.69m48.14m23.00--6.07--2,831.89-3.01-3.010.00272.480.0004----739.13-53.13-96.30-68.57-------134,723.50-775.06----0.00-----18.128.83------
Pelthos Therapeutics Inc0.00-7.36m49.03m4.00---------12.40-12.400.00-6.790.00----0.00-297.84-----------------25.62---------7.78------
CervoMed Inc9.31m-18.67m49.17m15.00--1.42--5.28-2.14-2.141.073.980.3997--11.43620,547.30-80.17-54.89-93.42-60.99-----200.58-428.45----0.00--36.29---650.08------
Propanc Biopharma Inc0.00-55.21m49.35m1.00--2.73-----168.14-168.140.001.560.00-------489.35---759.66-------------106.700.0644------35.61------
Renovaro Inc0.00-67.01m49.73m25.00--0.5308-----0.4327-0.43270.000.54430.00----0.00-40.61-39.86-47.81-42.11-----------10.460.0634-------103.23---37.12--
Gain Therapeutics Inc0.00-20.93m49.95m23.00--8.41-----0.8868-0.88680.000.20110.00----0.00-159.74-79.58-258.86-95.32-------19,975.78----0.0689---100.00--8.34--10.39--
Adicet Bio Inc0.00-117.32m50.20m152.00--0.311-----1.29-1.290.001.950.00----0.00-48.44-36.24-52.09-39.41-------813.80----0.00------17.90--32.77--
OS Therapies Inc0.00-13.27m51.42m4.00---------0.7949-0.79490.000.02880.00----0.00-426.54-----------------9.140.00-------37.51------
ABVC Biopharma Inc508.39k-1.81m52.16m16.00--8.85--102.61-0.1434-0.14340.03920.35140.0347--0.707631,774.38-15.15-105.17-32.38-217.0099.9075.19-437.11-2,124.210.2166-2.440.1706--234.31-6.2037.05------
Cue Biopharma Inc7.99m-40.58m52.38m41.00--6.53--6.56-0.6644-0.66440.12780.10640.2097--11.42194,902.40-106.51-60.20-190.46-73.56-----507.87-683.99----0.339--69.1621.8419.83--7.32--
Avalo Therapeutics Inc441.00k-21.10m53.71m23.000.22640.4380.7329121.7821.9121.910.049611.320.0034----19,173.9155.68-94.60356.71-128.31164.8581.1116,556.01-790.66----0.00---77.08-42.05-11.37------
Jupiter Neurosciences Inc0.00-3.33m54.62m4.00--17.82-----0.104-0.1040.000.0926------0.00---383.24-----------902.90---20.740.0456------49.00------
Adlai Nortye Ltd (ADR)0.00-51.87m55.35m123.00--2.17-----1.62-1.620.000.69070.00----0.00-51.49---97.48-------------27.170.5165------52.51------
Maia Biotechnology Inc0.00-19.70m56.07m13.00--11.07-----0.8202-0.82020.000.1670.00----0.00-191.49-208.29-371.24-373.18------------0.00-------17.61------
Data as of Jul 03 2025. Currency figures normalised to Cue Biopharma Inc's reporting currency: US Dollar USD

Institutional shareholders

17.58%Per cent of shares held by top holders
HolderShares% Held
Bleichroeder LPas of 31 Mar 20255.00m7.89%
The Vanguard Group, Inc.as of 31 Mar 20252.30m3.64%
Park City Capital LLCas of 05 Jun 20241.00m1.58%
Geode Capital Management LLCas of 31 Mar 2025693.89k1.10%
BlackRock Fund Advisorsas of 31 Mar 2025559.80k0.88%
Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Mar 2025478.50k0.76%
Sigma Planning Corp.as of 31 Mar 2025326.26k0.52%
Bank of America, NA (Private Banking)as of 31 Mar 2025324.34k0.51%
Advisory Research, Inc.as of 31 Mar 2025257.23k0.41%
1919 Investment Counsel LLCas of 31 Mar 2025196.56k0.31%
More ▼
Data from 05 Jun 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.